CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 108 enrolled
Drug / intervention
Oxygen Therapy +3 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04171037
NCT04171037N/ACompleted
CompareCT.gov

A Pilot Study of FDA Approved Optiflow™ THRIVE Versus Standard Non-Rebreathers in Patients With Potential High Risk of Airway Obstruction During Total Intravenous Anesthesia (TIVA) While Undergoing Interventional Radiology Procedures

M.D. Anderson Cancer Center·interventional·Posted Nov 20, 2019·Updated Jul 24, 2025

In Brief

A clinical study evaluating Oxygen Therapy, Questionnaire Administration, and 1 other intervention for Obstructive Sleep Apnea. Completed, enrolled 108 participants across 1 site.

Detailed Summary

This trial studies how well Optiflow THRIVE works in delivering oxygen to patients during total intravenous anesthesia while undergoing radiology procedures. The Optiflow THRIVE is an oxygen administration device that delivers high-flow and humidified oxygen through the nose. The Optiflow THRIVE device may improve oxygen delivery and reduce breathing complications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 20, 2019
Enrollment StartOct 4, 2019
Primary CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 6.6 years ago

Interventions

Oxygen Therapyprocedure

Receive oxygen via Optiflow THRIVE

Oxygen Therapyprocedure

Receive oxygen via non-rebreather

Questionnaire Administrationother

Ancillary studies

Optiflow THRIVEdevice

Oxygen Administration